Vor Biopharma Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. Vor is a clinical-stage cell and genome engineering company developing therapies for acute myeloid leukemia (AML). It has no approved products and has generated no product revenue.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $94.3 million | $64.6 million | +$29.8 million |
| General and administrative expense | $31.7 million | $28.9 million | +$2.9 million |
| Total operating expenses | $126.0 million | $93.4 million | +$32.6 million |
| Net loss | $117.9 million | $92.1 million | Loss widened $25.8 million |
| Net loss per share, basic and diluted | $1.75 | $2.33 | Loss per share narrowed |
| Net cash used in operating activities | $100.3 million | $85.1 million | Cash use increased $15.1 million |
| Cash, cash equivalents and marketable securities at year-end | $137.2 million | $230.2 million | Down $93.0 million |
Higher R&D spending reflected clinical and manufacturing work on trem-cel and VCAR33 ALLO, platform research and the Editas license. Higher interest income partly offset increased operating expenses. Profit margins are not meaningful because the company had no revenue. Operating cash use exceeded net loss partly because of non-cash expenses and working-capital movements.
At December 31, 2023, current assets were $140.8 million and current liabilities were $15.6 million. The company reported no financial debt in the supplied filing text; it did report $35.7 million of operating lease liabilities. Management estimated that year-end cash, cash equivalents and marketable securities would fund operating and capital needs into the second half of 2025, subject to its assumptions and operating plans. It stated that additional capital will be needed and is not assured.
Business progress and changes
- Trem-cel: In the Phase 1/2a VBP101 study, all eight patients in the reported data had primary neutrophil engraftment, with median engraftment at 10 days. Three of three patients treated with Mylotarg had reported hematologic protection from deep cytopenias through repeat doses. These are early, small-sample findings, not evidence of efficacy or approval.
- Mylotarg dose escalation to 1.0 mg/m2 had commenced. Vor expected further VBP101 engraftment and protection data in the second half of 2024.
- VCAR33 ALLO: The first patient was dosed in Phase 1/2 VBP301 in January 2024. Vor expected to treat additional patients in the first half of 2024 and report initial study data in the second half of 2024.
- Vor is exploring trem-cel in myelodysplastic syndrome and advancing preclinical programs involving other targets, including CD123, CLL-1 and EMR2. The proposed trem-cel plus VCAR33 Treatment System remains investigational.
Outlook, risks and unusual items
- Vor expects continued significant losses and higher R&D spending as clinical programs advance. It may need further equity, debt, collaboration or other financing; equity issuance could dilute shareholders. At year-end, $120.1 million remained available under its Stifel at-the-market facility.
- Development is early-stage and subject to clinical, regulatory, manufacturing and funding uncertainty. Risks include serious or delayed adverse events from genome-edited cells or CAR-T therapy, off-target genetic changes, transplant failure, trial enrollment delays, and dependence on third-party suppliers and licensed intellectual property.
- Clinical programs involve combination or sequential treatments. Vor noted potential dependencies on Mylotarg supply, safety and labeling, and the possibility that regulators could require additional evidence or cross-labeling arrangements.
- Market adoption and economics are uncertain: any future product would require approval, adequate manufacturing and reimbursement, and acceptance of novel gene-engineered therapies.
- The company had $340.1 million in accumulated deficit and reported no material legal proceedings. Its auditor gave an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to internal control effectiveness.
Most important facts for investors to verify
- Subsequent VBP101 results, including engraftment, safety, durability of hematologic protection and outcomes as Mylotarg dosing escalates.
- VBP301 enrollment, safety and early response data, including whether donor-derived VCAR33 ALLO can be manufactured consistently and shows clinical activity.
- Cash burn, actual financing needs and whether the stated runway into the second half of 2025 remains valid; assess potential dilution from the ATM facility or other financing.
- Manufacturing readiness, third-party supply availability, license obligations and any regulatory requirements that could affect trial timing or the proposed combined treatment system.